雅各臣科研製藥(02633.HK)完成增持品牌中藥業務
格隆匯 7 月 30日丨雅各臣科研製藥(02633.HK)公佈,有關收購事項及戰略投資協議項下交易。收購事項及戰略投資協議已於2020年7月30日完成。收購事項完成後,公司間接持有目標公司已發行股本總數的98%,而為結算應付代價,代價股份按與戰略投資者根據戰略投資協議所作認購相同的健倍苗苗估值,於完成時發行予賣方。每股代價股份的發行價為1港元,與根據戰略投資協議的每股認購價相同。戰略投資者作出認購及釐定收購事項涉及代價股份所依據的健倍苗苗投資前估值,屬健倍苗苗的估值範圍內,該範圍由獨立專業估值師以市場法參考可資比較已上市之藥物製造及分銷企業釐定,並因健倍苗苗仍為一傢俬有公司而其股份缺乏流通性,故採用了折讓係數。
於收購事項及戰略投資協議完成後,公司、賣方及戰略投資者分別直接及間接(視情況而定)持有健倍苗苗經擴大股本的85.04%、3.53%及11.43%。健倍苗苗的財務業績將繼續於集團財務報表內綜合入賬。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.